Key result
Accidental overcorrection of severe hyponatremia in a patient with chronic heart failure was successfully managed by administering hypotonic fluids and desmopressin to prevent osmotic demyelination syndrome.
Why the study?
Does cautious correction of severe symptomatic hyponatremia with hypertonic saline, furosemide, hypotonic fluids, and desmopressin prevent central pontine myelinolysis in a patient with chronic heart failure?
Case Report (n=1)
Does cautious correction of severe symptomatic hyponatremia with hypertonic saline, furosemide, hypotonic fluids, and desmopressin prevent central pontine myelinolysis in a patient with chronic heart failure?
In patients with chronic heart failure and severe symptomatic hyponatremia, accidental overcorrection can be safely managed with hypotonic fluids and desmopressin to prevent osmotic demyelination syndrome.
Answers are grounded in this paper and cite their sources.
May inform re-lowering in overcorrected hyponatremia with heart failure; leaves open prospective confirmation to prevent demyelination.
This review aims at summarizing essential aspects of epidemiology and pathophysiology of hyponatremia in chronic heart failure (CHF), to set the ground for a practical as well as evidence-based approach to treatment. As a guide through the discussion of the available evidence, a clinical case of hyponatremia associated with CHF is presented. For this case, the severe neurological signs at presentation justified an emergency treatment with hypertonic saline plus furosemide, as indicated. Subsequently, as the neurological emergency began to subside, the reversion of the trend toward hyponatremia overcorrection was realized by continuous infusion of hypotonic solutions, and administration of desmopressin, so as to prevent the very feared risk of an osmotic demyelination syndrome. This very disabling complication of the hyponatremia correction is then briefly outlined. Moreover, the possible advantages related to systematic correction of the hyponatremia that occurs in the course of CHF are mentioned. Additionally, the case of tolvaptan, a vasopressin receptor antagonist, is concisely presented in order to underline the different views that have led to different norms in Europe with respect to the USA or Japan as regards the use of this drug as a therapeutic resource against the hyponatremia.
No takes yet. Share an insight, caveat, or question.
Vecchis et al. (2017) conducted a case report in Symptomatic hyponatremia in chronic heart failure (n=1). Hypotonic fluids and desmopressin was evaluated on Serum sodium correction speed and prevention of osmotic demyelination syndrome. Accidental overcorrection of severe hyponatremia in a patient with chronic heart failure was successfully managed by administering hypotonic fluids and desmopressin to prevent osmotic demyelination syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: